LOOK TO
PUSH RET
BACK

GAVRETO is the only once-daily therapy designed to selectively target RET in mNSCLC1

*See the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC for detailed recommendations, including other preferred treatment options.2
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
mNSCLC=metastatic non–small cell lung cancer; RET=rearranged during transfection.

Efficacy data for GAVRETO
GAVRETO demonstrated a robust and durable response in RET+ mNSCLC1
Safety for GAVRETO
GAVRETO was generally well
tolerated in RET+ mNSCLC1
Resources for your patients
Get access and
patient support

GAV_LNG-24006 0924

References:

 

1. GAVRETO® [Package insert], South San Francisco, CA: Rigel Pharmaceuticals, Inc.

 

2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.7.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 2, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.